Limits...
The expression of aldehyde dehydrogenase 1 (ALDH1) in ovarian carcinomas and its clinicopathological associations: a retrospective study.

Huang R, Li X, Holm R, Trope CG, Nesland JM, Suo Z - BMC Cancer (2015)

Bottom Line: Statistical analyses showed that high ALDH1 expression in tumor cells was significantly associated with histological subtypes, early FIGO stage, well differentiation grade and better survival probability (p < 0.05).The expression of ALDH1 in the stromal cells had no clinicopathological associations in the present study (p > 0.05).More studies are warranted to find out the mechanisms for this.

View Article: PubMed Central - PubMed

Affiliation: Departments of Pathology, The Norwegian Radium Hospital, Oslo University Hospital, Ullernchausseen 70, 0379, Oslo, Norway.

ABSTRACT

Background: Aldehyde dehydrogenase 1 (ALDH1) is widely used as a specific cancer stem cell marker in a variety of cancers, and may become a promising target for cancer therapy. However, the role of its expression in tumor cells and the microenvironment in different cancers is still controversial.

Methods: To clarify the clinicopathological effect of ALDH1 expression in ovarian carcinoma, a series of 248 cases of paraffin-embedded formalin fixed ovarian carcinoma tissues with long term follow-up information were studied by immunohistochemistry.

Results: The immunostaining of ALDH1was variably detected in both tumor cells and the stromal cells, although the staining in tumor cells was not as strong as that in stromal cells. Statistical analyses showed that high ALDH1 expression in tumor cells was significantly associated with histological subtypes, early FIGO stage, well differentiation grade and better survival probability (p < 0.05). The expression of ALDH1 in the stromal cells had no clinicopathological associations in the present study (p > 0.05).

Conclusioms: High expression of cancer stem cell marker ALDH1 in ovarian carcinoma cells may thus portend a favorable prognosis, but its expression in tumor microenvironment may have no role in tumor behavior of ovarian carcinomas. More studies are warranted to find out the mechanisms for this.

No MeSH data available.


Related in: MedlinePlus

ALDH1 expression in ovarian carcinoma cells and stromal cells. a A poor differentiated ovarian carcinoma showed negative immunostaining in tumor cells for ALDH1, while most of the stromal cells surrounding tumor cells were strongly positive (100×). b High magnitude was used in the same case in A, showing clear negative tumor cells and positive stromal cells (400×). c Variable expression levels of ALDH1 in tumor cells were displayed in a moderately differentiated ovarian carcinoma. The stromal cells were all positive (100×). d A part of figure (b) was enlarged, showing weakly positive staining in most of the tumor cells and the staining was limited to the membrane and the cytoplasm (400×). e Tumor cells in a well differentiated ovarian carcinoma were all strongly positive while the stromal cells were negative (100×). f High magnitude of a part of figure (E) displayed strongly positive staining for ALDH1 in most of the epithelial tumor cells/hyperplasia epithelial cells (400×)
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4494797&req=5

Fig1: ALDH1 expression in ovarian carcinoma cells and stromal cells. a A poor differentiated ovarian carcinoma showed negative immunostaining in tumor cells for ALDH1, while most of the stromal cells surrounding tumor cells were strongly positive (100×). b High magnitude was used in the same case in A, showing clear negative tumor cells and positive stromal cells (400×). c Variable expression levels of ALDH1 in tumor cells were displayed in a moderately differentiated ovarian carcinoma. The stromal cells were all positive (100×). d A part of figure (b) was enlarged, showing weakly positive staining in most of the tumor cells and the staining was limited to the membrane and the cytoplasm (400×). e Tumor cells in a well differentiated ovarian carcinoma were all strongly positive while the stromal cells were negative (100×). f High magnitude of a part of figure (E) displayed strongly positive staining for ALDH1 in most of the epithelial tumor cells/hyperplasia epithelial cells (400×)

Mentions: Immunoreactive ALDH1 was variably detected in the ovarian carcinoma cells and the stromal cells in all the ovarian primary tumor samples (Fig. 1). Endothelial cells of blood vessel were always positive for ALDH1. The immunostaining was limited to cytoplasm and cell membrane. Out of the total 248 samples, 98 cases were negative in tumor cells for ALDH1, and 111 cases had a low expression level and 39 cases had a high expression level (Table 2). Generally, the tumor cells from well-differentiated carcinomas tended to highly expressed ALDH1 and those from poor-differentiated carcinomas tended to express ALDH1 lowly. Compared with the tumor cells, ALDH1 expression in the stromal cells was generally rather strong. The numbers of negative, low expression and high expression of ALDH1 in the stromal cells were 13 cases, 61 cases and 174 cases, respectively (Table 3).Fig. 1


The expression of aldehyde dehydrogenase 1 (ALDH1) in ovarian carcinomas and its clinicopathological associations: a retrospective study.

Huang R, Li X, Holm R, Trope CG, Nesland JM, Suo Z - BMC Cancer (2015)

ALDH1 expression in ovarian carcinoma cells and stromal cells. a A poor differentiated ovarian carcinoma showed negative immunostaining in tumor cells for ALDH1, while most of the stromal cells surrounding tumor cells were strongly positive (100×). b High magnitude was used in the same case in A, showing clear negative tumor cells and positive stromal cells (400×). c Variable expression levels of ALDH1 in tumor cells were displayed in a moderately differentiated ovarian carcinoma. The stromal cells were all positive (100×). d A part of figure (b) was enlarged, showing weakly positive staining in most of the tumor cells and the staining was limited to the membrane and the cytoplasm (400×). e Tumor cells in a well differentiated ovarian carcinoma were all strongly positive while the stromal cells were negative (100×). f High magnitude of a part of figure (E) displayed strongly positive staining for ALDH1 in most of the epithelial tumor cells/hyperplasia epithelial cells (400×)
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4494797&req=5

Fig1: ALDH1 expression in ovarian carcinoma cells and stromal cells. a A poor differentiated ovarian carcinoma showed negative immunostaining in tumor cells for ALDH1, while most of the stromal cells surrounding tumor cells were strongly positive (100×). b High magnitude was used in the same case in A, showing clear negative tumor cells and positive stromal cells (400×). c Variable expression levels of ALDH1 in tumor cells were displayed in a moderately differentiated ovarian carcinoma. The stromal cells were all positive (100×). d A part of figure (b) was enlarged, showing weakly positive staining in most of the tumor cells and the staining was limited to the membrane and the cytoplasm (400×). e Tumor cells in a well differentiated ovarian carcinoma were all strongly positive while the stromal cells were negative (100×). f High magnitude of a part of figure (E) displayed strongly positive staining for ALDH1 in most of the epithelial tumor cells/hyperplasia epithelial cells (400×)
Mentions: Immunoreactive ALDH1 was variably detected in the ovarian carcinoma cells and the stromal cells in all the ovarian primary tumor samples (Fig. 1). Endothelial cells of blood vessel were always positive for ALDH1. The immunostaining was limited to cytoplasm and cell membrane. Out of the total 248 samples, 98 cases were negative in tumor cells for ALDH1, and 111 cases had a low expression level and 39 cases had a high expression level (Table 2). Generally, the tumor cells from well-differentiated carcinomas tended to highly expressed ALDH1 and those from poor-differentiated carcinomas tended to express ALDH1 lowly. Compared with the tumor cells, ALDH1 expression in the stromal cells was generally rather strong. The numbers of negative, low expression and high expression of ALDH1 in the stromal cells were 13 cases, 61 cases and 174 cases, respectively (Table 3).Fig. 1

Bottom Line: Statistical analyses showed that high ALDH1 expression in tumor cells was significantly associated with histological subtypes, early FIGO stage, well differentiation grade and better survival probability (p < 0.05).The expression of ALDH1 in the stromal cells had no clinicopathological associations in the present study (p > 0.05).More studies are warranted to find out the mechanisms for this.

View Article: PubMed Central - PubMed

Affiliation: Departments of Pathology, The Norwegian Radium Hospital, Oslo University Hospital, Ullernchausseen 70, 0379, Oslo, Norway.

ABSTRACT

Background: Aldehyde dehydrogenase 1 (ALDH1) is widely used as a specific cancer stem cell marker in a variety of cancers, and may become a promising target for cancer therapy. However, the role of its expression in tumor cells and the microenvironment in different cancers is still controversial.

Methods: To clarify the clinicopathological effect of ALDH1 expression in ovarian carcinoma, a series of 248 cases of paraffin-embedded formalin fixed ovarian carcinoma tissues with long term follow-up information were studied by immunohistochemistry.

Results: The immunostaining of ALDH1was variably detected in both tumor cells and the stromal cells, although the staining in tumor cells was not as strong as that in stromal cells. Statistical analyses showed that high ALDH1 expression in tumor cells was significantly associated with histological subtypes, early FIGO stage, well differentiation grade and better survival probability (p < 0.05). The expression of ALDH1 in the stromal cells had no clinicopathological associations in the present study (p > 0.05).

Conclusioms: High expression of cancer stem cell marker ALDH1 in ovarian carcinoma cells may thus portend a favorable prognosis, but its expression in tumor microenvironment may have no role in tumor behavior of ovarian carcinomas. More studies are warranted to find out the mechanisms for this.

No MeSH data available.


Related in: MedlinePlus